186 related articles for article (PubMed ID: 12887267)
21. Trial of antiretroviral for HIV prevention on hold.
Ahmad K
Lancet Infect Dis; 2004 Oct; 4(10):597. PubMed ID: 15470760
[No Abstract] [Full Text] [Related]
22. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
23. Can AIDS drug also prevent HIV infection?
AIDS Read; 2004 Jan; 14(1):14. PubMed ID: 14959699
[No Abstract] [Full Text] [Related]
24. Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.
Deeks SG; Barditch-Crovo P; Collier A; Smith A; Miller M; McGowan I; Coakley DF
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):336-9. PubMed ID: 11707669
[TBL] [Abstract][Full Text] [Related]
25. Tenofovir disoproxil fumarate.
Chapman T; McGavin J; Noble S
Drugs; 2003; 63(15):1597-608. PubMed ID: 12887265
[TBL] [Abstract][Full Text] [Related]
26. Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate.
Quinn KJ; Emerson CR; Dinsmore WW; Donnelly CM
Int J STD AIDS; 2010 Feb; 21(2):150-1. PubMed ID: 20090006
[No Abstract] [Full Text] [Related]
27. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Breton G; Alexandre M; Duval X; Prie D; Peytavin G; Leport C; Vildei JL
Scand J Infect Dis; 2004; 36(6-7):527-8. PubMed ID: 15307594
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
[TBL] [Abstract][Full Text] [Related]
29. [96-week treatment outcome confirms long term efficacy of tenofovir DF].
Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796
[No Abstract] [Full Text] [Related]
30. Prodrug of tenofovir diphosphate approved for combination HIV therapy.
Thompson CA
Am J Health Syst Pharm; 2002 Jan; 59(1):18. PubMed ID: 11813460
[No Abstract] [Full Text] [Related]
31. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?
Saumoy M; Vidal F; Peraire J; Sauleda S; Vea AM; Viladés C; Ribera E; Richart C
AIDS; 2004 Aug; 18(12):1741-2. PubMed ID: 15280790
[No Abstract] [Full Text] [Related]
32. Tenofovir disoproxil fumarate.
Grim SA; Romanelli F
Ann Pharmacother; 2003 Jun; 37(6):849-59. PubMed ID: 12773076
[TBL] [Abstract][Full Text] [Related]
33. From the Food and Drug Administration.
Schwetz BA
JAMA; 2001 Dec; 286(21):2660. PubMed ID: 11730423
[No Abstract] [Full Text] [Related]
34. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
Shere-Wolfe KD; Verley JR
Clin Infect Dis; 2002 Nov; 35(9):1137. PubMed ID: 12384851
[No Abstract] [Full Text] [Related]
35. Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
Stephan C
Expert Opin Pharmacother; 2008 May; 9(7):1197-209. PubMed ID: 18422476
[TBL] [Abstract][Full Text] [Related]
36. The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.
McCormack S; Fidler S; Fisher M; ;
Int J STD AIDS; 2012 Jan; 23(1):1-4. PubMed ID: 22362679
[No Abstract] [Full Text] [Related]
37. Warning issued on non-response rates.
AIDS Patient Care STDS; 2003 Oct; 17(10):539. PubMed ID: 14588094
[No Abstract] [Full Text] [Related]
38. Tenofovir gel studied.
AIDS Patient Care STDS; 2002 Aug; 16(8):401-2. PubMed ID: 12227991
[No Abstract] [Full Text] [Related]
39. [Conclusions. Tenofovir].
Mallolas J
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():62-4. PubMed ID: 19195439
[No Abstract] [Full Text] [Related]
40. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Feinberg J
AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
